Dasatinib Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation for an Isolated Central Nervous System Blast Crisis in Chronic Myelogenous Leukemia

Nishimoto, Mitsutaka; Nakamae, Hirohisa; Koh, Ki-Ryang; Kosaka, Saori; Matsumoto, Kana; Morita, Kunihiko; Koh, Hideo; Nakane, Takahiko; Ohsawa, Masahiko; Hino, Masayuki
August 2013
Acta Haematologica;2013, Vol. 130 Issue 2, p111
Academic Journal
A 22-year-old male with Ph-positive chronic myelogenous leukemia (CML) was started on treatment with imatinib. After 12 months of therapy, he achieved a complete cytogenetic response (CCyR). Although the CCyR persisted in his bone marrow, he developed an isolated CML blast crisis in his central nervous system (CNS) after 29 months of therapy. He underwent allogeneic hematopoietic stem cell transplantation (HSCT) following combination therapy with dasatinib, intrathecal chemotherapy and cranial irradiation. Subsequently, 168 days after allogeneic HSCT, he was started on dasatinib maintenance therapy to prevent a CNS relapse. Thirty-eight months after allogeneic HSCT, he has sustained a complete molecular response in both bone marrow and CNS. We believe dasatinib has the potential to prevent CNS relapse if used for maintenance therapy after allogeneic HSCT. Copyright © 2013 S. Karger AG, Basel


Related Articles

  • Challenges for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors. Oyekunle, Anthony; Klyuchnikov, Evgeny; Ocheni, Sunday; Kröger, Nicolaus; Zander, Axel R.; Baccarani, Michele; Bacher, Ulrike // Acta Haematologica;2011, Vol. 126 Issue 1, p30 

    Following the introduction of the tyrosine kinase inhibitor (TKI) imatinib in the treatment of chronic myeloid leukemia (CML) patients, the allogeneic hematopoietic stem cell transplantation (HSCT) scene in CML has changed dramatically. The number of patients receiving HSCT in first chronic...

  • Early Use of Drastic Therapy. Weinberg, Kenneth I. // New England Journal of Medicine;5/19/2005, Vol. 352 Issue 20, p2124 

    Focuses on the treatment of Krabbe's disease, also known as globoid-cell leukodystrophy. Claim that Krabbe's disease is an inborn error of lipid metabolism; Impact of Krabbe's disease on the central nervous system; Potential for improved status following enzyme replacement; Details of the...

  • Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT. Suttorp, M. // Bone Marrow Transplantation;Oct2008 Supplement, Vol. 42, pS40 

    Allogeneic haematopoietic SCT (HSCT) induces CRs in most patients with CML. With the excellent short-term treatment results induced by imatinib (IMA), attitudes have changed and only a minority of children are now transplanted upfront. This review addresses the role of IMA in children with CML,...

  • BY THE NUMBERS.  // Hem/Onc Today;6/10/2014, Vol. 15 Issue 11, p1 

    Statistics are given on the improved results of hematopoietic stem cell transplantation (HSCT) on patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) given with pre-transplant imatinib based on overall survival (OS), relapse, and non-release mortality rates.

  • Imatinib prior to HSCT improved outcomes in Ph+ALL.  // Hem/Onc Today;6/10/2014, Vol. 15 Issue 11, p11 

    The article focuses on the positive results of pre-transplant imatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) subjected to allogeneic hematopoietic stem cell transplantation (HSCT).

  • The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis. Schwartz, S.; Reisman, A.; Troke, P. F. // Infection;Jun2011, Vol. 39 Issue 3, p201 

    Purpose: The efficacy of voriconazole against fungal central nervous system (CNS) infections was examined retrospectively. Methods: Voriconazole-treated patients with proven (137) or probable (55) CNS infections were identified in the voriconazole database (114) and the literature (78)....

  • The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia. Ercaliskan, Abdulkadir; Eskazan, A. Emre // Cancer (0008543X);Oct2018, Vol. 124 Issue 19, p3806 

    Although the majority of patients with chronic myeloid leukemia do well with treatment with tyrosine kinase inhibitors (TKIs), some patients still have inferior outcomes. There are many factors that might play a part, including the different BCR-ABL1 transcript types at baseline. The current...

  • Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation. Hilgendorf, Inken; Wolff, Daniel; Junghanss, Christian; Kahl, Christoph; Leithaeuser, Malte; Steiner, Beate; Casper, Jochen; Freund, Mathias // Annals of Hematology;Dec2008, Vol. 87 Issue 12, p1009 

    Liposomal cytarabine has been proven to be useful for the prevention and intrathecal treatment of neoplastic meningitis. It has no demonstrable myelosuppressive effects and may therefore be an attractive alternative for prophylaxis and treatment of the central nervous system (CNS) relapse after...

  • Management of Red Teeth in an International Patient with X-Linked Adrenoleukodystrophy. Petrova, Elena; Miller, Weston P.; Myers, Sandra L.; Karp, Jeffrey M. // Pediatric Dentistry;Nov/Dec2015, Vol. 37 Issue 7, p550 

    Childhood cerebral X-linked adrenoleukodystrophy is a progressive, central nervous system, and endocrine disorder that typically leads to total neurologic disability and, eventually, death without appropriate, timely medical therapy. Hematopoietic stem cell transplantation has been found...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics